This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Threshold Pharmaceuticals, Inc.
Drug Names(s): Lonidamine
Description: TH-070 is an orally administered small molecule that has been reported to inhibit glycolysis by inactivating hexokinase, the enzyme that catalyzes the first step in glycolysis. Hypoxic tumor cells and certain prostate cells depend on glycolysis for their energy production. TH-070 kills prostate cells, reducing the size of the prostate in animals, and therefore may provide an effective treatment for BPH.
Additional information available to subscribers only: